Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has appointed Daniel Brennan as an independent member of its Board of Directors, expanding the board from 10 to 11 members, according to a company statement.

Brennan brings more than 35 years of finance experience in the healthcare industry, including over 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. He most recently served as Boston Scientific's Executive Vice President and Chief Financial Officer, where he oversaw global finance functions and corporate business development before retiring last year.

Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex, commented on the appointment: "Dan's extensive financial leadership experience and deep understanding of global healthcare businesses will bring an important perspective to the Vertex Board."

Brennan currently serves on the Boards of Directors of Waters Corporation and Madrigal Pharmaceuticals, where he also chairs the Audit Committee. He holds a B.S. in finance and investments and an M.B.A. from Babson College and is a certified public accountant.